

Connecting via Winsock to STN

Welcome to STN International! Enter x:x

LOGINID:SSPTANXR1625

PASSWORD:

TERMINAL (ENTER 1, 2, 3, OR ?):2

* * * * * Welcome to STN International * * * * *

NEWS 1 Web Page for STN Seminar Schedule - N. America
NEWS 2 AUG 15 CAOLD to be discontinued on December 31, 2008
NEWS 3 OCT 07 EPFULL enhanced with full implementation of EPC2000
NEWS 4 OCT 07 Multiple databases enhanced for more flexible patent
number searching
NEWS 5 OCT 22 Current-awareness alert (SDI) setup and editing
enhanced
NEWS 6 OCT 22 WPIDS, WPINDEX, and WPIX enhanced with Canadian PCT
Applications
NEWS 7 OCT 24 CHEMLIST enhanced with intermediate list of
pre-registered REACH substances
NEWS 8 NOV 21 CAS patent coverage to include exemplified prophetic
substances identified in English-, French-, German-,
and Japanese-language basic patents from 2004-present
NEWS 9 NOV 26 MARPAT enhanced with FSORT command
NEWS 10 NOV 26 MEDLINE year-end processing temporarily halts
availability of new fully-indexed citations
NEWS 11 NOV 26 CHEMSAFE now available on STN Easy
NEWS 12 NOV 26 Two new SET commands increase convenience of STN
searching
NEWS 13 DEC 01 ChemPort single article sales feature unavailable

NEWS EXPRESS JUNE 27 08 CURRENT WINDOWS VERSION IS V8.3,
AND CURRENT DISCOVER FILE IS DATED 23 JUNE 2008.

NEWS HOURS STN Operating Hours Plus Help Desk Availability
NEWS LOGIN Welcome Banner and News Items
NEWS IPC8 For general information regarding STN implementation of IPC 8

Enter NEWS followed by the item number or name to see news on that
specific topic.

All use of STN is subject to the provisions of the STN Customer
agreement. Please note that this agreement limits use to scientific
research. Use for software development or design or implementation
of commercial gateways or other similar uses is prohibited and may
result in loss of user privileges and other penalties.

* * * * * STN Columbus * * * * *

FILE 'HOME' ENTERED AT 20:10:16 ON 02 DEC 2008

=> file reg

COST IN U.S. DOLLARS

SINCE FILE

TOTAL

ENTRY

SESSION

FULL ESTIMATED COST

0.42

0.42

FILE 'REGISTRY' ENTERED AT 20:11:39 ON 02 DEC 2008
USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.
PLEASE SEE "HELP USAGETERMS" FOR DETAILS.
COPYRIGHT (C) 2008 American Chemical Society (ACS)

Property values tagged with IC are from the ZIC/VINITI data file
provided by InfoChem.

STRUCTURE FILE UPDATES: 30 NOV 2008 HIGHEST RN 1077629-73-2
DICTIONARY FILE UPDATES: 30 NOV 2008 HIGHEST RN 1077629-73-2

New CAS Information Use Policies, enter HELP USAGETERMS for details.

TSCA INFORMATION NOW CURRENT THROUGH July 5, 2008.



Please note that search-term pricing does apply when
conducting SmartSELECT searches.

REGISTRY includes numerically searchable data for experimental and
predicted properties as well as tags indicating availability of
experimental property data in the original document. For information
on property searching in REGISTRY, refer to:

<http://www.cas.org/support/stngen/stndoc/properties.html>

=>

Uploading C:\Program Files\Stnexp\Queries\10581833d.str



```

chain nodes :
10 17 18 19 20 23 24
ring nodes :
1 2 3 4 5 6 7 8 9
chain bonds :
2-10 4-17 6-19 6-20 7-18 8-23 8-24
ring bonds :
1-2 1-5 2-3 3-4 4-5 4-6 5-9 6-7 7-8 8-9
exact/norm bonds :
1-2 1-5 2-3 2-10 3-4 4-5 4-6 4-17 5-9 6-7 6-19 6-20 7-8 7-18 8-9
8-23 8-24
isolated ring systems :
containing 1 :
```

G1:C,N

G2:C,O,N

G3:O,N

G4:H,Cy,Ak

G5:H,Ak

G6:H,CH3

Match level :


1:Atom 2:Atom 3:Atom 4:Atom 5:Atom 6:Atom 7:Atom 8:Atom 9:Atom 10:CLASS
17:CLASS 18:CLASS 19:CLASS 20:CLASS 23:CLASS 24:CLASS

L1 STRUCTURE UPLOADED

=> d l1

L1 HAS NO ANSWERS

L1 STR



G1 C,N

G2 C,O,N

G3 O,N

G4 H,Cy,Ak

G5 H,Ak

G6 H,Me

Structure attributes must be viewed using STN Express query preparation.

=> s l1 full

FULL SEARCH INITIATED 20:12:00 FILE 'REGISTRY'

FULL SCREEN SEARCH COMPLETED - 526790 TO ITERATE

100.0% PROCESSED 526790 ITERATIONS

85 ANSWERS

SEARCH TIME: 00.00.15

L2 85 SEA SSS FUL L1

=> file caplus

COST IN U.S. DOLLARS

SINCE FILE

TOTAL

ENTRY

SESSION

FULL ESTIMATED COST

178.36

178.78

FILE 'CAPLUS' ENTERED AT 20:12:20 ON 02 DEC 2008

USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.

PLEASE SEE "HELP USAGETERMS" FOR DETAILS.

COPYRIGHT (C) 2008 AMERICAN CHEMICAL SOCIETY (ACS)

Copyright of the articles to which records in this database refer is held by the publishers listed in the PUBLISHER (PB) field (available for records published or updated in Chemical Abstracts after December 26, 1996), unless otherwise indicated in the original publications.

The CA Lexicon is the copyrighted intellectual property of the American Chemical Society and is provided to assist you in searching databases on STN. Any dissemination, distribution, copying, or storing of this information, without the prior written consent of CAS, is strictly prohibited.

FILE COVERS 1907 - 2 Dec 2008 VOL 149 ISS 23
FILE LAST UPDATED: 1 Dec 2008 (20081201/ED)

Caplus now includes complete International Patent Classification (IPC) reclassification data for the third quarter of 2008.

Effective October 17, 2005, revised CAS Information Use Policies apply. They are available for your review at:

<http://www.cas.org/legal/infopolicy.html>



=> s l2 full

L3 8 L2

=> d ibib abs hitstr tot

ACCESSION NUMBER: 2008:1071012 CAPLUS
 DOCUMENT NUMBER: 149:332352
 TITLE: Preparation of heteroaryl amides as PIM kinase inhibitors
 INVENTOR(S): Burger, Matthew; Lindvall, Mika; Han, Wooseok; Lan, Jiong; Nishiguchi, Gisele; Shafer, Cynthia; Bellamacina, Cornelia; Huh, Kay; Atallah, Gordana; McBride, Christopher; Antonios-McCrea, William, Jr.; Zavorotinskaya, Tatiana; Walter, Annette; Garcia, Pablo
 PATENT ASSIGNEE(S): Novartis Vaccines and Diagnostics, Inc., USA
 SOURCE: PCT Int. Appl., 306pp.
 CODEN: PIXXD2
 DOCUMENT TYPE: Patent
 LANGUAGE: English
 FAMILY ACC. NUM. COUNT: 1
 PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2008106692	A1	20080904	WO 2008-US55724	20080303
W: AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KN, KP, KR, KZ, LA, LC, LK, LR, LS, LT, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RS, RU, SC, SD, SE, SG, SK, SL, SM, SV, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW RW: AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MT, NL, NO, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG, BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				
PRIORITY APPLN. INFO.:			US 2007-892444P	P 20070301
			US 2008-23777P	P 20080125
OTHER SOURCE(S):		MARPAT 149:332352		
GI				



AB The title compds. I [X1-X4 = CR2, N; provided that not more than two of X1-X4 can be N; Y = (un)substituted NH2, alkoxy, cyclohexyl, aryl, etc.; Z1-Z3 = CR2, N; provided that not more than one of Z1-Z3 can be N; R1 = H, halo, alkyl, etc.; R2 = H, halo, OH, etc.], compns. and methods of inhibition of kinase activity associated with tumorigenesis in a human or animal subject are provided. In certain embodiments, the compds. I and compns. are effective to inhibit the activity of at least one serine/threonine kinase or receptor tyrosine kinase. Over six hundred

comps. I were prepared Thus, reacting 4-(piperidin-1-yl)pyridin-3-amine with 3-aminopyrazine-2-carboxylic acid afforded 61% II. Exemplified comps. I were tested against Pim1, Pim2, Pim3 and other kinases (data given). The new comps. I and compns. may be used either alone or in combination with at least one addnl. agent for the treatment of a serine/threonine kinase- or receptor tyrosine kinase-mediated disorder, such as cancer.

IT 1052715-49-7P 1052715-51-1P 1052715-52-2P

1052715-53-3P


RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)

(preparation of heteroaryl amides as PIM kinase inhibitors for treating cancer)

RN 1052715-49-7 CAPLUS

CN Oxazolo[4,5-c]pyridine-5(4H)-carboxylic acid, hexahydro-2-oxo-, phenylmethyl ester, (3aR,7aS)- (CA INDEX NAME)


Absolute stereochemistry.



RN 1052715-51-1 CAPLUS

CN Oxazolo[4,5-c]pyridine-5(4H)-carboxylic acid, hexahydro-2-oxo-, phenylmethyl ester, (3aS,7aR)- (CA INDEX NAME)


Absolute stereochemistry.



RN 1052715-52-2 CAPLUS

CN Oxazolo[4,5-c]pyridine-3,5(2H,4H)-dicarboxylic acid, tetrahydro-2-oxo-, 3-(1,1-dimethylethyl) 5-(phenylmethyl) ester, (3aR,7aS)- (CA INDEX NAME)


Absolute stereochemistry.



RN 1052715-53-3 CAPLUS

CN Oxazolo[4,5-c]pyridine-3,5(2H,4H)-dicarboxylic acid, tetrahydro-2-oxo-,
3-(1,1-dimethylethyl) 5-(phenylmethyl) ester, (3aS,7aR)- (CA INDEX NAME)

Absolute stereochemistry.



REFERENCE COUNT:


10

THERE ARE 10 CITED REFERENCES AVAILABLE FOR THIS
RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

ACCESSION NUMBER: 2005:1290311 CAPLUS
 DOCUMENT NUMBER: 144:36339
 TITLE: Preparation of cinnamide,
 3-benzylidenepiperidin-2-one, phenylpropynamide
 compounds as amyloid β production inhibitors
 INVENTOR(S): Kimura, Teiji; Kawano, Koki; Doi, Eriko; Kitazawa,
 Noritaka; Shin, Kogyoku; Miyagawa, Takehiko; Kaneko,
 Toshihiko; Ito, Koichi; Takaishi, Mamoru; Sasaki,
 Takeo; Hagiwara, Hiroaki
 PATENT ASSIGNEE(S): Eisai Co., Ltd., Japan
 SOURCE: PCT Int. Appl., 679 pp.
 CODEN: PIXXD2
 DOCUMENT TYPE: Patent
 LANGUAGE: Japanese
 FAMILY ACC. NUM. COUNT: 2
 PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2005115990	A1	20051208	WO 2005-JP9537	20050525
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NG, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SM, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW				
RW: BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
AU 2005247746	A1	20051208	AU 2005-247746	20050525
CA 2566094	A1	20051208	CA 2005-2566094	20050525
US 20060004013	A1	20060105	US 2005-136355	20050525
EP 1757591	A1	20070228	EP 2005-743758	20050525
R: AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LI, LT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR, AL, BA, HR, LV, MK, YU				
CN 1972916	A	20070530	CN 2005-80020584	20050525
BR 2005011504	A	20080122	BR 2005-11504	20050525
JP 4101852	B2	20080618	JP 2006-513906	20050525
IN 2006DN06740	A	20070831	IN 2006-DN6740	20061114
US 20080070902	A1	20080320	US 2006-596723	20061116
MX 2006PA13534	A	20070510	MX 2006-PA13534	20061122
NO 2006005789	A	20070226	NO 2006-5789	20061214
JP 2008101015	A	20080501	JP 2007-306088	20071127
PRIORITY APPLN. INFO.:			JP 2004-155790	A 20040526
			JP 2004-310909	A 20041026
			JP 2006-513906	A3 20050525
			WO 2005-JP9537	W 20050525

OTHER SOURCE(S): MARPAT 144:36339
 GI



AB The title compds. represented by the formula (I) (wherein Ar1 = imidazolyl optionally substituted by one to three substituents; Ar2 = pyridinyl, pyrimidinyl, or Ph group optionally substituted by one to three substituents; X1 = C.tplbond.C or optionally substituted CH:CH; R1, R2 = H, halo, HO, cyano, NO2, optionally substituted C1-6 alkyl, C3-8 cycloalkyl, C1-6 alkoxy, NH2, CONH2, saturated N-containing, heterocyclyl, etc.)

or pharmacol. acceptable salts thereof are prepared These compds. inhibit the production of amyloid β 40 and amyloid β 42 proteins from amyloid precursor protein (APP) and are useful for the treatment of neurodegenerative diseases caused by amyloid β proteins such as Alzheimer's disease, senile dementia, Down's syndrome, and amyloidosis. Thus, a solution of 4.00 g 3-methoxy-4-(4-methyl-1H-imidazol-1-yl)benzaldehyde in 40 mL THF was treated successively with 4.00 mL diethylphosphonoacetic acid Et ester and 932 mg LiOH.H2O and stirred at room temperature overnight to give 4.61 g (E)-3-[3-methoxy-4-(4-methyl-1H-imidazol-1-yl)phenyl]acrylic acid which (2.20 g) was dissolved in 30 mL DMF, successively treated with 2.30 g 3-phenylbenzylamine hydrochloride, 4.75 mL diisopropylethylamine, and 1.38 g HOBT, and stirred at room temperature overnight to give 3.30 g (E)-N-biphenyl-3-ylmethyl-3-[3-methoxy-4-(4-methyl-1H-imidazol-1-yl)phenyl]acrylamide (II). II and (E)-N-(3-methoxypropyl)-N-(naphthalen-1-ylmethyl)-3-[3-methoxy-4-(4-methyl-1H-imidazol-1-yl)phenyl]acrylamide showed IC50 of 70 and 60 nM, resp., for inhibiting the production of A β 42 protein in nerve cells of rat embryo.

IT 870842-47-0P


RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)

(preparation of cinnamide, 3-benzylidenepiperidin-2-one, phenylpropynamide compds. as amyloid β production inhibitors for treatment of neurodegenerative diseases)

RN 870842-47-0 CAPLUS

CN 2H-Pyrrolo[2,3-c]pyridin-2-one, octahydro-6-[(2E)-3-[3-methoxy-4-(4-methyl-1H-imidazol-1-yl)phenyl]-1-oxo-2-propen-1-yl]-1-phenyl-, (3aR,7aS)-rel- (CA INDEX NAME)

Relative stereochemistry.
Double bond geometry as shown.



REFERENCE COUNT:

11

THERE ARE 11 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L3 ANSWER 3 OF 8 CAPLUS COPYRIGHT 2008 ACS on STN

ACCESSION NUMBER: 2005:523455 CAPLUS
DOCUMENT NUMBER: 143:38426
TITLE: Muscarinic agents as therapeutic compounds
INVENTOR(S): Buffat, Maxime; Thomas, Eric James; Davies, Robin
Havard
PATENT ASSIGNEE(S): Muscagen Limited, UK
SOURCE: PCT Int. Appl., 53 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2005054242	A1	20050616	WO 2004-GB5096	20041206
W:	AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW			
RW:	BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG			
EP 1697359	A1	20060906	EP 2004-805924	20041206
EP 1697359	B1	20081022		
R:	AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, HU, PL, SK, BA, HR, IS, YU			
JP 2007513136	T	20070524	JP 2006-542022	20041206
AT 411993	T	20081115	AT 2004-805924	20041206
US 20080039469	A1	20080214	US 2007-581833	20070413
PRIORITY APPLN. INFO.:			GB 2003-28295	A 20031205
			WO 2004-GB5096	W 20041206

OTHER SOURCE(S): MARPAT 143:38426

AB Muscarinic agonists with M1 selectivity which are useful as agents for stimulating the cognitive functions of the brain.

IT 853658-68-1P


RL: BSU (Biological study, unclassified); SPN (Synthetic preparation);

BIOL (Biological study); PREP (Preparation)

(muscarinic agents as therapeutic compds.)

RN 853658-68-1 CAPLUS

CN Oxazolo[4,5-c]pyridin-2(3H)-one, 3a-cyclobutylhexahydro-7-(methoxymethyl)-3-(phenylmethyl)-, conjugate acid (1:1) (CA INDEX NAME)



REFERENCE COUNT:

4

THERE ARE 4 CITED REFERENCES AVAILABLE FOR THIS
RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L3 ANSWER 4 OF 8 CAPLUS COPYRIGHT 2008 ACS on STN

ACCESSION NUMBER: 2002:225541 CAPLUS

DOCUMENT NUMBER: 137:109013

TITLE: Stereoelectronic substituent effects in polyhydroxylated piperidines and hexahydropyridazines
AUTHOR(S): Jensen, Henrik Helligso; Lyngbye, Laila; Jensen, Astrid; Bols, Mikael

CORPORATE SOURCE: Department of Chemistry, University of Aarhus, Aarhus, 8000, Den.

SOURCE: Chemistry--A European Journal (2002), 8(5), 1218-1226
CODEN: CEUJED; ISSN: 0947-6539

PUBLISHER: Wiley-VCH Verlag GmbH

DOCUMENT TYPE: Journal

LANGUAGE: English

OTHER SOURCE(S): CASREACT 137:109013

AB From the pKa values of the conjugate acids of a large series of hydroxylated piperidines and hexahydropyridazines, a consistent difference in basicity was found between stereoisomers having an axial or equatorial hydroxyl (OH) group either β or γ to the amine. Compds. with an equatorial OH group in the 3-position were 0.8 pH units more acidic than otherwise identical compds. with an axial OH group, while compds. with an equatorial OH group in the 4-position relative to the amine were 0.4 pH units more acidic than the corresponding compound with an axial OH. A similar effect was observed for the COOMe substituent. The difference in electron-withdrawing power of axial and equatorial substituents was explained by a difference in charge-dipole interactions in the two systems. Since this stereoelectronic substituent effect causes differences in basicity in different conformers, certain piperidines and hexahydropyridazines were found to change conformation upon protonation. A method for predicting the pKa of piperidines which takes stereochem. into account is described.

IT 443649-05-6 443649-06-7


RL: PRP (Properties)

(basicity; stereoelectronic substituent effects in polyhydroxylated piperidines and hexahydropyridazines)

RN 443649-05-6 CAPLUS

CN Oxazolo[4,5-c]pyridin-2(3H)-one, hexahydro-7-(hydroxymethyl)-, (3aR,7R,7aR)-rel- (CA INDEX NAME)


Relative stereochemistry.



RN 443649-06-7 CAPLUS

CN Oxazolo[4,5-c]pyridin-2(3H)-one, hexahydro-7-(hydroxymethyl)-, (3aR,7S,7aS)-rel- (CA INDEX NAME)

Relative stereochemistry.




REFERENCE COUNT:

44

THERE ARE 44 CITED REFERENCES AVAILABLE FOR THIS
RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

ACCESSION NUMBER: 2000:602132 CAPLUS
 DOCUMENT NUMBER: 133:322028
 TITLE: General Route to 2,4,5-Trisubstituted Piperidines from Enantiopure β -Amino Esters. Total Synthesis of Pseudodistomin B Triacetate and Pseudodistomin F
 AUTHOR(S): Ma, Dawei; Sun, Haiying
 CORPORATE SOURCE: State Key Laboratory of Bioorganic and Natural Products Chemistry, Shanghai Institute of Organic Chemistry Chinese Academy of Sciences, Shanghai, 200032, Peop. Rep. China
 SOURCE: Journal of Organic Chemistry (2000), 65(19), 6009-6016
 CODEN: JOCEAH; ISSN: 0022-3263
 PUBLISHER: American Chemical Society
 DOCUMENT TYPE: Journal
 LANGUAGE: English
 OTHER SOURCE(S): CASREACT 133:322028
 GI



AB The Michael addition reaction of enantiopure β -amino esters with Me acrylate followed by Dieckmann condensation and enol silylation affords enol ethers I (R = BOC), which are hydrogenated with catalysis by Raney-Ni at 80 atm and 80 °C to provide 2,4,5-trisubstituted piperidines with high diastereoselectivity. In this case Ni-H attacks the C-C double bond from the direction of the 2-alkyl group to provide the products in which the 4-hydroxy group and 5-ester moiety are trans to the 2-alkyl group. While hydrogenation of enol ether I (R = H, R1 = OTBS) without a N-Boc protecting group gives the product in which 2,4,5-trisubstituted groups are all cis to each other. By using the diastereoselective hydrogenation products II (R1 = HO(CH₂)₅) and II (R1 = OH) as key intermediates, pseudodistomin B triacetate and pseudodistomin F are synthesized. The key steps for these transformations include Curtius rearrangement and Julia olefination.


IT 303007-78-5P 303007-79-6P 303007-80-9P
 303007-81-0P 303007-82-1P 303007-83-2P
 RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)

(total syntheses of Pseudodistomin B triacetate and Pseudodistomin F)

RN 303007-78-5 CAPLUS

CN Oxazolo[4,5-c]pyridine-5(4H)-carboxylic acid,
 hexahydro-6-(6-hydroxyhexyl)-2-oxo-, 1,1-dimethylethyl ester,
 (3aS,6R,7aR)- (CA INDEX NAME)


Absolute stereochemistry. Rotation (-).



RN 303007-79-6 CAPLUS

CN Oxazolo[4,5-c]pyridine-5(4H)-carboxylic acid,
hexahydro-2-oxo-6-[(6E)-8-oxo-6-octen-1-yl]-, 1,1-dimethylethyl ester,
(3aS,6R,7aR)- (CA INDEX NAME)


Absolute stereochemistry. Rotation (-).
Double bond geometry as shown.



RN 303007-80-9 CAPLUS

CN Oxazolo[4,5-c]pyridine-5(4H)-carboxylic acid,
hexahydro-2-oxo-6-(6E,8E)-6,8-tridecadien-1-yl-, 1,1-dimethylethyl ester,
(3aS,6R,7aR)- (CA INDEX NAME)


Absolute stereochemistry. Rotation (-).
Double bond geometry as shown.



RN 303007-81-0 CAPLUS


CN Oxazolo[4,5-c]pyridine-5(4H)-carboxylic acid,
hexahydro-6-(hydroxymethyl)-2-oxo-, 1,1-dimethylethyl ester, (3aS,6S,7aR)-
(CA INDEX NAME)

Absolute stereochemistry. Rotation (-).




RN 303007-82-1 CAPLUS
 CN Oxazolo[4,5-c]pyridine-5(4H)-carboxylic acid,
 hexahydro-2-oxo-6-[(phenylsulfonyl)methyl]-, 1,1-dimethylethyl ester,
 (3aS,6S,7aR)- (CA INDEX NAME)

Absolute stereochemistry. Rotation (-).



RN 303007-83-2 CAPLUS
 CN Oxazolo[4,5-c]pyridine-5(4H)-carboxylic acid,
 hexahydro-2-oxo-6-(1E,3E,8E,10E)-1,3,8,10-pentadecatetraen-1-yl-,
 1,1-dimethylethyl ester, (3aS,6S,7aR)- (CA INDEX NAME)

Absolute stereochemistry. Rotation (+).
 Double bond geometry as shown.



REFERENCE COUNT: 34 THERE ARE 34 CITED REFERENCES AVAILABLE FOR THIS
 RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L3 ANSWER 6 OF 8 CAPLUS COPYRIGHT 2008 ACS on STN

ACCESSION NUMBER: 2000:139683 CAPLUS

DOCUMENT NUMBER: 132:347768

TITLE: Synthesis of 3-substituted isofagomine analogues using an unusual syn hydrogenation reaction

AUTHOR(S): Lohse, Anders; Jensen, Henrik H.; Bach, Peter; Bols, Mikael

CORPORATE SOURCE: Department of Chemistry, University of Aarhus, Aarhus, DK-8000, Den.

SOURCE: Perkin 1 (2000), (5), 659-665

CODEN: PERKF9; ISSN: 1470-4358

PUBLISHER: Royal Society of Chemistry

DOCUMENT TYPE: Journal

LANGUAGE: English

OTHER SOURCE(S): CASREACT 132:347768

AB Isofagomine (3,4-dihydroxy-5-(hydroxymethyl)piperidine) and analogs are found to be strong inhibitors of glycosidases, and are therefore of potential interest in treatment of various disorders. Starting from cheap and readily available materials we have developed a new diastereoselective synthesis of 3,4,5-trisubstituted piperidines of the isofagomine type. (\pm)-3-Amino-3-deoxyisofagomine and a series of 11 closely related structures were synthesized via three key intermediates in relatively few and high yielding steps. The biol. activity of these compds. was investigated towards several enzymes, and new inhibitors of glycosidases were found.

IT 268729-90-4P 268729-91-5P 268729-92-6P


RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); BIOL (Biological study); PREP (Preparation)

(synthesis of 3-substituted isofagomine analogs as glycosidase inhibitors)

RN 268729-90-4 CAPLUS

CN Oxazolo[4,5-c]pyridin-2(3H)-one, hexahydro-7-(hydroxymethyl)-, hydrochloride (1:1), (3aR,7R,7aS)-rel- (CA INDEX NAME)

Relative stereochemistry.




● HCl

RN 268729-91-5 CAPLUS

CN Oxazolo[4,5-c]pyridin-2(3H)-one, hexahydro-7-(hydroxymethyl)-, hydrochloride (1:1), (3aR,7S,7aS)-rel- (CA INDEX NAME)


Relative stereochemistry.



● HCl

RN 268729-92-6 CAPLUS
 CN Oxazolo[4,5-c]pyridin-2(3H)-one, hexahydro-7-(hydroxymethyl)-,
 hydrochloride (1:1), (3aR,7R,7aR)-rel- (CA INDEX NAME)


Relative stereochemistry.



● HCl

IT 268729-98-2P 268729-99-3P 268730-00-3P
 RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT
 (Reactant or reagent)
 (synthesis of 3-substituted isofagomine analogs as glycosidase
 inhibitors)
 RN 268729-98-2 CAPLUS
 CN Oxazolo[4,5-c]pyridine-5(4H)-carboxylic acid,
 hexahydro-2-oxo-7-[[2-(trimethylsilyl)ethoxy]methyl]-, 1,1-dimethylethyl
 ester, (3aR,7R,7aS)-rel- (CA INDEX NAME)


Relative stereochemistry.



RN 268729-99-3 CAPLUS

CN Oxazolo[4,5-c]pyridine-5(4H)-carboxylic acid,
hexahydro-2-oxo-7-[[2-(trimethylsilyl)ethoxy]methyl]-, 1,1-dimethylethyl
ester, (3aR,7S,7aS)-rel- (CA INDEX NAME)


Relative stereochemistry.



RN 268730-00-3 CAPLUS

CN Oxazolo[4,5-c]pyridine-5(4H)-carboxylic acid,
hexahydro-2-oxo-7-[[2-(trimethylsilyl)ethoxy]methyl]-, 1,1-dimethylethyl
ester, (3aR,7R,7aR)-rel- (CA INDEX NAME)

Relative stereochemistry.



REFERENCE COUNT:

36

THERE ARE 36 CITED REFERENCES AVAILABLE FOR THIS
RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

ACCESSION NUMBER: 1999:292474 CAPLUS
 DOCUMENT NUMBER: 131:18915
 TITLE: Diastereoselective synthesis of 2,4,5-trisubstituted piperidines from enantiopure β -amino esters
 AUTHOR(S): Ma, Dawei; Sun, Haiying
 CORPORATE SOURCE: State Key Laboratory of Bioorganic and Natural Products Chemistry, Shanghai Institute of Organic Chemistry, Chinese Academy of Sciences, Shanghai, 200032, Peop. Rep. China
 SOURCE: Tetrahedron Letters (1999), 40(18), 3609-3612
 CODEN: TELEAY; ISSN: 0040-4039
 PUBLISHER: Elsevier Science Ltd.
 DOCUMENT TYPE: Journal
 LANGUAGE: English


AB Reaction of (R)- β -amino esters with Me acrylate followed by Dieckmann condensation and enol silylation afforded the enol ethers, which were hydrogenated with catalysis by Raney-Ni to provide 2,4,5-trisubstituted piperidines with high diastereoselectivity.

IT 226214-00-2P
 RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)
 (diastereoselective preparation of trisubstituted piperidines from enantiopure β -amino esters)

RN 226214-00-2 CAPLUS

CN Oxazolo[4,5-c]pyridine-5(4H)-carboxylic acid, hexahydro-2-oxo-6-pentadecyl-, 1,1-dimethylethyl ester, (3aS,6R,7aR)- (CA INDEX NAME)

Absolute stereochemistry.




IT 226213-99-6P
 RL: SPN (Synthetic preparation); PREP (Preparation)
 (diastereoselective preparation of trisubstituted piperidines from enantiopure β -amino esters)

RN 226213-99-6 CAPLUS

CN Oxazolo[4,5-c]pyridine-5(4H)-carboxylic acid, hexahydro-2-oxo-6-propyl-, 1,1-dimethylethyl ester, (3aS,6R,7aR)- (CA INDEX NAME)

Absolute stereochemistry.



RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L3 ANSWER 8 OF 8 CAPLUS COPYRIGHT 2008 ACS on STN

ACCESSION NUMBER: 1999:27845 CAPLUS
DOCUMENT NUMBER: 130:95849
TITLE: Dipeptide derivatives as growth hormone secretagogues
INVENTOR(S): Carpino, Philip Albert; Griffith, David Andrew;
Lefker, Bruce Allen
PATENT ASSIGNEE(S): Pfizer Inc., USA
SOURCE: PCT Int. Appl., 246 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 9858947	A1	19981230	WO 1998-IB873	19980605
W:	AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CU, CZ, DE, DK, EE, ES, FI, GB, GE, GH, HU, ID, IL, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, UA, UG, US, UZ, VN, YU, ZW			
RW:	GH, GM, KE, LS, MW, SD, SZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, ML, MR, NE, SN, TD, TG			
AU 9874454	A	19990104	AU 1998-74454	19980605
EP 1001970	A1	20000524	EP 1998-921680	19980605
EP 1001970	B1	20070307		
R:	AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, PT, IE, FI, CY			
JP 2000516639	T	20001212	JP 1999-504026	19980605
JP 3514774	B2	20040331		
AT 356139	T	20070315	AT 1998-921680	19980605
ES 2283055	T3	20071016	ES 1998-921680	19980605
US 6251902	B1	20010626	US 1999-380887	19990908
US 20010041703	A1	20011115	US 2001-822738	20010330
US 6525047	B2	20030225		
US 20020002165	A1	20020103	US 2001-822109	20010330
US 6429313	B2	20020806		
US 20020042415	A1	20020411	US 2001-822095	20010330
US 6432945	B2	20020813		
US 20020065284	A1	20020530	US 2001-823051	20010330
US 6433171	B2	20020813		
US 38524	E1	20040601	US 2002-270816	20021015
US 20030216399	A1	20031120	US 2003-371315	20030221
US 6953791	B2	20051011		
US 20040006063	A1	20040108	US 2003-371330	20030221
US 6924280	B2	20050802		
US 20040009984	A1	20040115	US 2003-371953	20030221
US 6951850	B2	20051004		
JP 2004043476	A	20040212	JP 2003-271589	20030707
JP 3676789	B2	20050727		
JP 2004043477	A	20040212	JP 2003-271598	20030707
JP 3676791	B2	20050727		
JP 2004067685	A	20040304	JP 2003-271592	20030707
JP 3676790	B2	20050727		
PRIORITY APPLN. INFO.:			US 1997-50764P	P 19970625
			JP 1999-504026	A3 19980605
			WO 1998-IB873	W 19980605
			US 1999-380887	A3 19990908
			US 2001-822738	A3 20010330


OTHER SOURCE(S): MARPAT 130:95849

AB Dipeptide derivs. HET-COCR3R4NX4CO-R6-NR7R8 [HET is a heterocyclic moiety; R3 = certain (un)substituted ring systems (A1), alkyl, A1-alkyl, etc.; R4 = H, alkyl, cycloalkyl or CR3R4 is a ring system; X4 is H, alkyl, or X4 and R4 form a ring; R6 is a bond or Z1(CH2)aCX5X5a(CH2)b, where a and b are 0-3, X5 and X5a are H, CF3, A1, (un)substituted alkyl or CX5X5a is a ring or the carbon atom bearing X5 and X5a forms one or two alkylene bridges with the nitrogen atom bearing R7 and R8, Z1 = bond, O, NH or imino group; R7, R8 = H, (un)substituted alkyl or R7R8N forms a ring] were prepared as growth hormone secretagogues. Thus, 2-amino-N-[2-(8a(S)-benzyl-3-oxotetrahydrooxazolo[3,4-a]pyrazin-7-yl)-1(R)-(3,5-dichlorobenzoyloxymethyl)-2-oxoethyl]-2-methylpropionamide hydrochloride was prepared from 1,2,4-piperazinetricarboxylic acid 1-benzyl 4-tert-Bu 2-Me ester, N-tert-butoxycarbonyl- α -methylalanine, N-tert-butoxy-D-serine, and 1,3-dichloro-5-chloromethylbenzene.

IT 218952-94-4P 218952-95-5P 218952-96-6P
218952-97-7P
RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)
(preparation of dipeptide derivs. as growth hormone secretagogues)


RN 218952-94-4 CAPLUS

CN Oxazolo[4,5-c]pyridine-5(4H)-carboxylic acid, hexahydro-2-oxo-3a-(2-pyridinylmethyl)-, 1,1-dimethylethyl ester (CA INDEX NAME)




RN 218952-95-5 CAPLUS

CN Oxazolo[4,5-c]pyridine-5(4H)-carboxylic acid, hexahydro-3-methyl-2-oxo-3a-(2-pyridinylmethyl)-, 1,1-dimethylethyl ester (CA INDEX NAME)



RN 218952-96-6 CAPLUS

CN Oxazolo[4,5-c]pyridin-2(3H)-one, hexahydro-3-methyl-3a-(2-pyridinylmethyl)-, hydrochloride (1:2) (CA INDEX NAME)




● 2 HCl

RN 218952-97-7 CAPLUS

CN Carbamic acid, [2-[[[(1R)-2-[hexahydro-3-methyl-2-oxo-3a-(2-pyridinylmethyl)oxazolo[4,5-c]pyridin-5(4H)-yl]-2-oxo-1-[(phenylmethoxy)methyl]ethyl]amino]-1,1-dimethyl-2-oxoethyl]-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.



IT 218950-28-8P 218951-25-8P 218951-26-9P
 218951-27-0P 218951-28-1P 218951-29-2P
 218951-30-5P 218951-31-6P 218951-32-7P
 218951-33-8P 218951-34-9P 218951-35-0P
 218951-36-1P 218951-37-2P 218951-40-7P
 218951-43-0P 218951-45-2P 218951-46-3P
 218951-47-4P 218951-48-5P 218951-49-6P
 218951-50-9P 218951-51-0P 218951-52-1P
 218951-53-2P 218951-54-3P 218951-55-4P
 218951-56-5P 218951-57-6P 218951-58-7P
 218951-59-8P 218951-60-1P 218951-61-2P
 218951-62-3P 218951-63-4P 218951-64-5P
 218952-16-0P 218953-79-8P 218953-80-1P
 218953-81-2P 218953-82-3P 218953-83-4P
 218953-84-5P 218953-85-6P 218953-86-7P
 218954-36-0P 218954-38-2P 218954-40-6P
 218954-42-8P 218954-43-9P 218954-45-1P
 218954-47-3P 218954-49-5P

RL: SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological


study); PREP (Preparation); USES (Uses)

(preparation of dipeptide derivs. as growth hormone secretagogues)

RN 218950-28-8 CAPLUS

CN Propanamide, 2-amino-N-[(1R)-2-[hexahydro-3-methyl-2-oxo-3a-(2-pyridinylmethyl)oxazolo[4,5-c]pyridin-5(4H)-yl]-2-oxo-1-[(phenylmethoxy)methyl]ethyl]-2-methyl-, hydrochloride (1:1) (CA INDEX NAME)

Absolute stereochemistry.




● HCl

RN 218951-25-8 CAPLUS

CN Propanamide, 2-amino-N-[(1R)-2-[hexahydro-2-oxo-3a-(phenylmethyl)oxazolo[4,5-c]pyridin-5(4H)-yl]-2-oxo-1-[(phenylmethoxy)methyl]ethyl]-2-methyl- (CA INDEX NAME)


Absolute stereochemistry.



RN 218951-26-9 CAPLUS

CN Propanamide, 2-amino-N-[(1R)-2-[hexahydro-2-oxo-3a-(phenylmethyl)oxazolo[4,5-c]pyridin-5(4H)-yl]-1-(1H-indol-3-ylmethyl)-2-oxoethyl]-2-methyl- (CA INDEX NAME)


Absolute stereochemistry.



RN 218951-27-0 CAPLUS

CN Propanamide, 2-amino-N-[(1R)-2-[hexahydro-3-methyl-2-oxo-3a-(phenylmethyl)oxazolo[4,5-c]pyridin-5(4H)-yl]-1-(1H-indol-3-ylmethyl)-2-oxoethyl]-2-methyl- (CA INDEX NAME)


Absolute stereochemistry.



RN 218951-28-1 CAPLUS

CN Propanamide, 2-amino-N-[(1R)-2-(hexahydro-2-oxooxazolo[4,5-c]pyridin-5(4H)-yl)-2-oxo-1-[(phenylmethoxy)methyl]ethyl]-2-methyl- (CA INDEX NAME)


Absolute stereochemistry.



RN 218951-29-2 CAPLUS

CN Propanamide, 2-amino-N-[(1R)-2-[hexahydro-2-oxo-3a-(phenylmethoxy)oxazolo[4,5-c]pyridin-5(4H)-yl]-1-[(1-methyl-1H-indol-3-yl)methyl]-2-oxoethyl]-2-methyl- (CA INDEX NAME)


Absolute stereochemistry.



RN 218951-30-5 CAPLUS

CN Propanamide, 2-amino-N-[(1R)-2-[hexahydro-2-oxo-3a-(phenylmethyl)oxazolo[4,5-c]pyridin-5(4H)-yl]-2-oxo-1-[(2-pyridinylmethoxy)methyl]ethyl]-2-methyl- (CA INDEX NAME)


Absolute stereochemistry.



RN 218951-31-6 CAPLUS

CN Propanamide, 2-amino-N-[(1R)-2-[hexahydro-2-oxo-3a-(phenylmethyl)oxazolo[4,5-c]pyridin-5(4H)-yl]-2-oxo-1-(5-thiazolylmethyl)ethyl]-2-methyl- (CA INDEX NAME)


Absolute stereochemistry.



RN 218951-32-7 CAPLUS

CN Propanamide, 2-amino-N-[(1S)-2-[hexahydro-2-oxo-3a-(phenylmethyl)oxazolo[4,5-c]pyridin-5(4H)-yl]-2-oxo-1-[[(phenylmethyl)thio]methyl]ethyl]-2-methyl- (CA INDEX NAME)


Absolute stereochemistry.



RN 218951-33-8 CAPLUS

CN Propanamide, 2-amino-N-[(1R)-2-[hexahydro-2-oxo-3a-(4-pyridinylmethyl)oxazolo[4,5-c]pyridin-5(4H)-yl]-2-oxo-1-[(phenylmethoxy)methyl]ethyl]-2-methyl- (CA INDEX NAME)


Absolute stereochemistry.



RN 218951-34-9 CAPLUS

CN Propanamide, 2-amino-N-[(1R)-2-[hexahydro-3-methyl-2-oxo-3a-(4-pyridinylmethyl)oxazolo[4,5-c]pyridin-5(4H)-yl]-2-oxo-1-[(phenylmethoxy)methyl]ethyl]-2-methyl- (CA INDEX NAME)


Absolute stereochemistry.



RN 218951-35-0 CAPLUS

CN Propanamide, 2-amino-N-[(1R)-2-[hexahydro-2-oxo-3a-(3-pyridinylmethyl)oxazolo[4,5-c]pyridin-5(4H)-yl]-2-oxo-1-[(phenylmethoxy)methyl]ethyl]-2-methyl- (CA INDEX NAME)


Absolute stereochemistry.



RN 218951-36-1 CAPLUS

CN Propanamide, 2-amino-N-[(1R)-2-[hexahydro-2-oxo-3a-(2-pyridinylmethyl)oxazolo[4,5-c]pyridin-5(4H)-yl]-2-oxo-1-[(phenylmethoxy)methyl]ethyl]-2-methyl- (CA INDEX NAME)


Absolute stereochemistry.



RN 218951-37-2 CAPLUS

CN Propanamide, 2-amino-N-[(1R)-2-[hexahydro-3-methyl-2-oxo-3a-(4-pyridinylmethyl)oxazolo[4,5-c]pyridin-5(4H)-yl]-2-oxo-1-[(2-pyridinylmethoxy)methyl]ethyl]-2-methyl- (CA INDEX NAME)


Absolute stereochemistry.



RN 218951-40-7 CAPLUS

CN Propanamide, 2-amino-N-[(1R)-2-[hexahydro-3-methyl-2-oxo-3a-(3-pyridinylmethyl)oxazolo[4,5-c]pyridin-5(4H)-yl]-2-oxo-1-[(phenylmethoxy)methyl]ethyl]-2-methyl- (CA INDEX NAME)


Absolute stereochemistry.



RN 218951-43-0 CAPLUS


CN Propanamide, 2-amino-N-[(1R)-2-[hexahydro-3-methyl-2-oxo-3a-(4-pyridinylmethyl)oxazolo[4,5-c]pyridin-5(4H)-yl]-1-(1H-indol-3-ylmethyl)-2-oxoethyl]-2-methyl- (CA INDEX NAME)

Absolute stereochemistry.




RN 218951-45-2 CAPLUS
 CN Propanamide, 2-amino-N-[(1R)-2-[hexahydro-2-oxo-3a-(4-pyridinylmethyl)oxazolo[4,5-c]pyridin-5(4H)-yl]-1-(1H-indol-3-ylmethyl)-2-oxoethyl]-2-methyl- (CA INDEX NAME)

Absolute stereochemistry.




RN 218951-46-3 CAPLUS
 CN Propanamide, 2-amino-N-[(1R)-2-[hexahydro-2-oxo-3a-(5-thiazolylmethyl)oxazolo[4,5-c]pyridin-5(4H)-yl]-2-oxo-1-[(phenylmethoxy)methyl]ethyl]-2-methyl- (CA INDEX NAME)

Absolute stereochemistry.



RN 218951-47-4 CAPLUS
 CN Propanamide, 2-amino-N-[(1R)-2-[hexahydro-2-oxo-3a-(2-phenylethyl)oxazolo[4,5-c]pyridin-5(4H)-yl]-2-oxo-1-[(phenylmethoxy)methyl]ethyl]-2-methyl- (CA INDEX NAME)


Absolute stereochemistry.



RN 218951-48-5 CAPLUS

CN Propanamide, 2-amino-N-[(1R)-2-[hexahydro-3-methyl-2-oxo-3a-(2-phenylethyl)oxazolo[4,5-c]pyridin-5(4H)-yl]-2-oxo-1-[(phenylmethoxy)methyl]ethyl]-2-methyl- (CA INDEX NAME)


Absolute stereochemistry.



RN 218951-49-6 CAPLUS

CN Propanamide, 2-amino-N-[(1R)-2-[hexahydro-3-methyl-2-oxo-3a-(3-pyridinylmethyl)oxazolo[4,5-c]pyridin-5(4H)-yl]-2-oxo-1-[[2-(trifluoromethyl)phenyl]methoxy)methyl]ethyl]-2-methyl- (CA INDEX NAME)


Absolute stereochemistry.



RN 218951-50-9 CAPLUS

CN Propanamide, 2-amino-N-[(1R)-2-[hexahydro-3-methyl-2-oxo-3a-(2-pyridinylmethyl)oxazolo[4,5-c]pyridin-5(4H)-yl]-2-oxo-1-[(phenylmethoxy)methyl]ethyl]-2-methyl- (CA INDEX NAME)


Absolute stereochemistry.



RN 218951-51-0 CAPLUS

CN Propanamide, 2-amino-N-[(1R)-1-[[2,4-difluorophenyl)methoxy)methyl]-2-[hexahydro-3-methyl-2-oxo-3a-(2-pyridinylmethyl)oxazolo[4,5-c]pyridin-5(4H)-yl]-2-oxoethyl]-2-methyl- (CA INDEX NAME)


Absolute stereochemistry.



RN 218951-52-1 CAPLUS

CN Propanamide, 2-amino-N-[(1R)-1-[[2,4-difluorophenyl)methoxy)methyl]-2-[hexahydro-2-oxo-3a-(3-pyridinylmethyl)oxazolo[4,5-c]pyridin-5(4H)-yl]-2-oxoethyl]-2-methyl- (CA INDEX NAME)


Absolute stereochemistry.



RN 218951-53-2 CAPLUS

CN Propanamide, 2-amino-N-[(1R)-1-[[2,4-difluorophenyl)methoxy)methyl]-2-[hexahydro-3-methyl-2-oxo-3a-(3-pyridinylmethyl)oxazolo[4,5-c]pyridin-5(4H)-yl]-2-oxoethyl]-2-methyl- (CA INDEX NAME)


Absolute stereochemistry.



RN 218951-54-3 CAPLUS

CN Propanamide, 2-amino-N-[(1R)-1-[[4-chlorophenyl)methoxy)methyl]-2-[hexahydro-3-methyl-2-oxo-3a-(3-pyridinylmethyl)oxazolo[4,5-c]pyridin-5(4H)-yl]-2-oxoethyl]-2-methyl- (CA INDEX NAME)


Absolute stereochemistry.



RN 218951-55-4 CAPLUS

CN Propanamide, 2-amino-N-[(1R)-2-[3-ethylhexahydro-2-oxo-3a-(3-pyridinylmethyl)oxazolo[4,5-c]pyridin-5(4H)-yl]-2-oxo-1-[(phenylmethoxy)methyl]ethyl]-2-methyl- (CA INDEX NAME)


Absolute stereochemistry.



RN 218951-56-5 CAPLUS

CN Propanamide, 2-amino-N-[(1R)-1-[[2-(4-difluorophenyl)methoxy]methyl]-2-[3-ethylhexahydro-2-oxo-3a-(3-pyridinylmethyl)oxazolo[4,5-c]pyridin-5(4H)-yl]-2-oxoethyl]-2-methyl- (CA INDEX NAME)


Absolute stereochemistry.



RN 218951-57-6 CAPLUS

CN Propanamide, 2-amino-N-[(1R)-1-[[2-(4-chlorophenyl)methoxy]methyl]-2-[3-ethylhexahydro-2-oxo-3a-(3-pyridinylmethyl)oxazolo[4,5-c]pyridin-5(4H)-yl]-2-oxoethyl]-2-methyl- (CA INDEX NAME)


Absolute stereochemistry.



RN 218951-58-7 CAPLUS

CN Propanamide, 2-amino-N-[(1R)-2-[hexahydro-2-oxo-3-(phenylmethyl)oxazolo[4,5-c]pyridin-5(4H)-yl]-2-oxo-1-[(phenylmethoxy)methyl]ethyl]-2-methyl- (CA INDEX NAME)


Absolute stereochemistry.



RN 218951-59-8 CAPLUS

CN Propanamide, 2-amino-N-[(1R)-2-[hexahydro-2-oxo-3-(phenylmethyl)oxazolo[4,5-c]pyridin-5(4H)-yl]-2-oxo-1-[(2-pyridinylmethoxy)methyl]ethyl]-2-methyl- (CA INDEX NAME)


Absolute stereochemistry.



RN 218951-60-1 CAPLUS

CN Propanamide, 2-amino-N-[(1R)-2-[hexahydro-2-oxo-3-(2-pyridinylmethyl)oxazolo[4,5-c]pyridin-5(4H)-yl]-2-oxo-1-[(phenylmethoxy)methyl]ethyl]-2-methyl- (CA INDEX NAME)

Absolute stereochemistry.




RN 218951-61-2 CAPLUS

CN Propanamide, 2-amino-N-[(1R)-1-[[2,4-difluorophenyl)methoxy)methyl]-2-

[hexahydro-2-oxo-3-(2-pyridinylmethyl)oxazolo[4,5-c]pyridin-5(4H)-yl]-2-oxoethyl]-2-methyl- (CA INDEX NAME)


Absolute stereochemistry.



RN 218951-62-3 CAPLUS

CN Propanamide, 2-amino-N-[(1R)-2-[hexahydro-2-oxo-3-(2-pyridinylmethyl)oxazolo[4,5-c]pyridin-5(4H)-yl]-2-oxo-1-[[[2-(trifluoromethyl)phenyl]methoxy]methyl]ethyl]-2-methyl- (CA INDEX NAME)


Absolute stereochemistry.



RN 218951-63-4 CAPLUS

CN Propanamide, 2-amino-N-[(1R)-2-[3a-[(2,6-dichloro-4-pyridinyl)methyl]hexahydro-2-oxooxazolo[4,5-c]pyridin-5(4H)-yl]-2-oxo-1-[(phenylmethoxy)methyl]ethyl]-2-methyl- (CA INDEX NAME)


Absolute stereochemistry.



RN 218951-64-5 CAPLUS

CN Propanamide, 2-amino-N-[(1R)-2-[hexahydro-2-oxo-3-(2-pyridinylmethyl)oxazolo[4,5-c]pyridin-5(4H)-yl]-2-oxo-1-[(2-pyridinylmethoxy)methyl]ethyl]-2-methyl- (CA INDEX NAME)


Absolute stereochemistry.



RN 218952-16-0 CAPLUS

CN Propanamide, 2-amino-N-[(1R)-2-[3-ethylhexahydro-2-oxo-3a-(2-pyridinylmethyl)oxazolo[4,5-c]pyridin-5(4H)-yl]-2-oxo-1-[(phenylmethoxy)methyl]ethyl]-2-methyl- (CA INDEX NAME)


Absolute stereochemistry.



RN 218953-79-8 CAPLUS

CN Propanamide, 2-amino-N-[(1R)-2-[(3aR,7aR)-hexahydro-2-oxo-3a-(phenylmethyl)oxazolo[4,5-c]pyridin-5(4H)-yl]-2-oxo-1-[(phenylmethoxy)methyl]ethyl]-2-methyl- (CA INDEX NAME)


Absolute stereochemistry.



RN 218953-80-1 CAPLUS

CN Propanamide, 2-amino-N-[(1R)-2-[(3aS,7aS)-hexahydro-2-oxo-3a-(phenylmethyl)oxazolo[4,5-c]pyridin-5(4H)-yl]-2-oxo-1-[(phenylmethoxy)methyl]ethyl]-2-methyl- (CA INDEX NAME)


Absolute stereochemistry.



RN 218953-81-2 CAPLUS

CN Propanamide, 2-amino-N-[(1R)-2-[(3aR,7aR)-hexahydro-3-methyl-2-oxo-3a-(3-pyridinylmethyl)oxazolo[4,5-c]pyridin-5(4H)-yl]-2-oxo-1-[(phenylmethoxy)methyl]ethyl]-2-methyl- (CA INDEX NAME)


Absolute stereochemistry.



RN 218953-82-3 CAPLUS

CN Propanamide, 2-amino-N-[(1R)-2-[(3aS,7aS)-hexahydro-3-methyl-2-oxo-3a-(3-pyridinylmethyl)oxazolo[4,5-c]pyridin-5(4H)-yl]-2-oxo-1-[(phenylmethoxy)methyl]ethyl]-2-methyl- (CA INDEX NAME)


Absolute stereochemistry.



RN 218953-83-4 CAPLUS

CN Propanamide, 2-amino-N-[(1R)-2-[(3aR,7aR)-hexahydro-3-methyl-2-oxo-3a-(phenylmethyl)oxazolo[4,5-c]pyridin-5(4H)-yl]-1-(1H-indol-3-ylmethyl)-2-oxoethyl]-2-methyl- (CA INDEX NAME)


Absolute stereochemistry.



RN 218953-84-5 CAPLUS

CN Propanamide, 2-amino-N-[(1R)-2-[(3aS,7aS)-hexahydro-3-methyl-2-oxo-3a-(phenylmethyl)oxazolo[4,5-c]pyridin-5(4H)-yl]-1-(1H-indol-3-ylmethyl)-2-oxoethyl]-2-methyl- (CA INDEX NAME)


Absolute stereochemistry.



RN 218953-85-6 CAPLUS

CN Propanamide, 2-amino-N-[(1R)-2-[(3aR,7aR)-hexahydro-2-oxo-3a-(2-pyridinylmethyl)oxazolo[4,5-c]pyridin-5(4H)-yl]-2-oxo-1-[(phenylmethoxy)methyl]ethyl]-2-methyl- (CA INDEX NAME)

Absolute stereochemistry.




RN 218953-86-7 CAPLUS

CN Propanamide, 2-amino-N-[(1R)-2-[(3aS,7aS)-hexahydro-2-oxo-3a-(2-

pyridinylmethyl)oxazolo[4,5-c]pyridin-5(4H)-yl]-2-oxo-1-
[(phenylmethoxy)methyl]ethyl]-2-methyl- (CA INDEX NAME)


Absolute stereochemistry.



RN 218954-36-0 CAPLUS

CN Propanamide, 2-amino-N-[(1R)-2-[(3aR,7aS)-hexahydro-2-oxo-3a-(phenylmethyl)oxazolo[4,5-c]pyridin-5(4H)-yl]-2-oxo-1-[(phenylmethoxy)methyl]ethyl]-2-methyl- (CA INDEX NAME)


Absolute stereochemistry.



RN 218954-38-2 CAPLUS

CN Propanamide, 2-amino-N-[(1R)-2-[(3aS,7aR)-hexahydro-2-oxo-3a-(phenylmethyl)oxazolo[4,5-c]pyridin-5(4H)-yl]-2-oxo-1-[(phenylmethoxy)methyl]ethyl]-2-methyl- (CA INDEX NAME)

Absolute stereochemistry.




RN 218954-40-6 CAPLUS

CN Propanamide, 2-amino-N-[(1R)-2-[(3aR,7aS)-hexahydro-3-methyl-2-oxo-3a-(3-


pyridinylmethyl)oxazolo[4,5-c]pyridin-5(4H)-yl]-2-oxo-1-
[(phenylmethoxy)methyl]ethyl]-2-methyl- (CA INDEX NAME)

Absolute stereochemistry.




RN 218954-42-8 CAPLUS
CN Propanamide, 2-amino-N-[(1R)-2-[(3aS,7aR)-hexahydro-3-methyl-2-oxo-3a-(3-pyridinylmethyl)oxazolo[4,5-c]pyridin-5(4H)-yl]-2-oxo-1-[(phenylmethoxy)methyl]ethyl]-2-methyl- (CA INDEX NAME)

Absolute stereochemistry.



RN 218954-43-9 CAPLUS
CN Propanamide, 2-amino-N-[(1R)-2-[(3aR,7aS)-hexahydro-3-methyl-2-oxo-3a-(phenylmethyl)oxazolo[4,5-c]pyridin-5(4H)-yl]-1-(1H-indol-3-ylmethyl)-2-oxoethyl]-2-methyl- (CA INDEX NAME)


Absolute stereochemistry.



RN 218954-45-1 CAPLUS

CN Propanamide, 2-amino-N-[(1R)-2-[(3aS,7aR)-hexahydro-3-methyl-2-oxo-3a-(phenylmethyl)oxazolo[4,5-c]pyridin-5(4H)-yl]-1-(1H-indol-3-ylmethyl)-2-oxoethyl]-2-methyl- (CA INDEX NAME)


Absolute stereochemistry.



RN 218954-47-3 CAPLUS

CN Propanamide, 2-amino-N-[(1R)-2-[(3aR,7aS)-hexahydro-2-oxo-3a-(2-pyridinylmethyl)oxazolo[4,5-c]pyridin-5(4H)-yl]-2-oxo-1-[(phenylmethoxy)methyl]ethyl]-2-methyl- (CA INDEX NAME)

Absolute stereochemistry.




RN 218954-49-5 CAPLUS

CN Propanamide, 2-amino-N-[(1R)-2-[(3aS,7aR)-hexahydro-2-oxo-3a-(2-

pyridinylmethyl)oxazolo[4,5-c]pyridin-5(4H)-yl]-2-oxo-1-
[(phenylmethoxy)methyl]ethyl]-2-methyl- (CA INDEX NAME)

Absolute stereochemistry.



REFERENCE COUNT:

3

THERE ARE 3 CITED REFERENCES AVAILABLE FOR THIS
RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

=> FIL STNGUIDE
COST IN U.S. DOLLARS

FULL ESTIMATED COST

SINCE FILE ENTRY	TOTAL SESSION
54.16	232.94

DISCOUNT AMOUNTS (FOR QUALIFYING ACCOUNTS)

CA SUBSCRIBER PRICE

SINCE FILE ENTRY	TOTAL SESSION
-6.40	-6.40

FILE 'STNGUIDE' ENTERED AT 20:25:27 ON 02 DEC 2008
USE IS SUBJECT TO THE TERMS OF YOUR CUSTOMER AGREEMENT
COPYRIGHT (C) 2008 AMERICAN CHEMICAL SOCIETY (ACS)

FILE CONTAINS CURRENT INFORMATION.
LAST RELOADED: Nov 21, 2008 (20081121/UP).